Despite aggressive treatments including surgery, radiotherapy and chemotherapy, the prognosis of high grade gliomas (HGG) remains poor. Since a curative option is not currently available, new therapeutic strategies are required to extend the progression-free interval and the overall survival ofglioma patients. The use of monoclonal antibodies (MoAbs) labelled with cytotoxic agents has demonstrated the potential to interfere with the growth of tumour. This article describes our experience in radioimmunotherapy (RIT) with monoclonal antibodies and tumour pretargeting with the Avidin-Biotin system, either in systemic and locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumour cell irradiation with radionuclides. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach, in combination with surgery, radiotherapy and chemotherapy.
|Number of pages||8|
|Publication status||Published - Dec 2007|
ASJC Scopus subject areas